2024 Q4 Form 10-Q Financial Statement

#000149315224043927 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q3
Revenue $741.1K $998.4K $796.1K
YoY Change -3.0% 25.41% 155.72%
Cost Of Revenue $384.4K $525.5K $563.8K
YoY Change -31.95% -6.79%
Gross Profit $223.1K $346.8K $232.3K
YoY Change 11.98% 49.27%
Gross Profit Margin 30.1% 34.74% 29.18%
Selling, General & Admin $1.949M $2.460M
YoY Change -20.77% 69.66%
% of Gross Profit 562.0% 1058.83%
Research & Development $948.8K $100.0K
YoY Change 848.75% 25.0%
% of Gross Profit 273.57% 43.04%
Depreciation & Amortization $241.6K $247.6K
YoY Change -2.41%
% of Gross Profit 69.67% 106.57%
Operating Expenses $2.621M $3.198M $2.869M
YoY Change 11.84% 11.49% 87.53%
Operating Profit -$2.264M -$2.725M -$2.526M
YoY Change 13.72% 7.87% 107.36%
Interest Expense $30.46K $90.00K
YoY Change -66.16%
% of Operating Profit
Other Income/Expense, Net $7.685K $30.46K $93.94K
YoY Change -48.68% -67.57% 2087.73%
Pretax Income -$2.695M -$2.430M
YoY Change 10.9% 100.83%
Income Tax
% Of Pretax Income
Net Earnings -$2.249M -$2.686M -$2.425M
YoY Change 14.21% 10.74% 100.71%
Net Earnings / Revenue -303.52% -268.99% -304.64%
Basic Earnings Per Share -$0.50 -$0.70 -$1.04
Diluted Earnings Per Share -$0.50 -$0.70 -$1.04
COMMON SHARES
Basic Shares Outstanding 4.387M shares 4.250M shares 2.330M shares
Diluted Shares Outstanding 4.536M shares 3.811M shares 2.330M shares

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.989M $190.0K
YoY Change 1999.7% -96.69%
Cash & Equivalents $2.242M $3.990M $186.4K
Short-Term Investments
Other Short-Term Assets $348.7K $396.2K $413.3K
YoY Change 5.15% -4.14% 177.52%
Inventory $701.3K $738.8K $965.1K
Prepaid Expenses
Receivables $266.1K $578.6K $567.5K
Other Receivables $648.3K $560.0K
Total Short-Term Assets $4.062M $6.479M $2.692M
YoY Change 37.93% 140.68% -67.2%
LONG-TERM ASSETS
Property, Plant & Equipment $537.2K $586.1K $664.9K
YoY Change -9.15% -11.85% 59.83%
Goodwill
YoY Change
Intangibles $3.903M $4.400M $4.872M
YoY Change -19.67% -9.69%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $4.622M $5.247M $6.009M
YoY Change -21.42% -12.68% 207.76%
TOTAL ASSETS
Total Short-Term Assets $4.062M $6.479M $2.692M
Total Long-Term Assets $4.622M $5.247M $6.009M
Total Assets $8.684M $11.73M $8.700M
YoY Change -1.62% 34.77% -14.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.834M $3.630M
YoY Change -49.47% 855.26%
Accrued Expenses $759.1K $630.0K
YoY Change 20.49% -34.38%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $499.6K $340.0K
YoY Change 46.94%
Total Short-Term Liabilities $4.403M $5.679M $6.846M
YoY Change -15.06% -17.05% 190.43%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $310.0K
YoY Change -100.0%
Other Long-Term Liabilities $97.84K $310.0K
YoY Change -68.44% -88.12%
Total Long-Term Liabilities $97.84K $620.0K
YoY Change -84.22% -76.25%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.403M $5.679M $6.846M
Total Long-Term Liabilities $97.84K $620.0K
Total Liabilities $4.481M $5.777M $7.464M
YoY Change -21.02% -22.61% 50.37%
SHAREHOLDERS EQUITY
Retained Earnings -$56.90M -$54.65M -$44.23M
YoY Change 23.15% 23.55% 36.59%
Common Stock $48.07K $43.78K $23.30K
YoY Change 225.66% 87.84% -84.35%
Preferred Stock
YoY Change
Treasury Stock (at cost) $1.00 $1.00 $14.00
YoY Change 0.0% -92.86%
Treasury Stock Shares
Shareholders Equity $4.366M $6.105M $1.356M
YoY Change
Total Liabilities & Shareholders Equity $8.684M $11.73M $8.700M
YoY Change -1.62% 34.77% -14.36%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income -$2.249M -$2.686M -$2.425M
YoY Change 14.21% 10.74% 100.71%
Depreciation, Depletion And Amortization $241.6K $247.6K
YoY Change -2.41%
Cash From Operating Activities -$2.387M -$1.312M
YoY Change 81.98% -30.73%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $42.45K
YoY Change
NET CHANGE
Cash From Operating Activities -$2.387M -$1.312M
Cash From Investing Activities
Cash From Financing Activities $42.45K
Net Change In Cash -$2.315M -$1.351M
YoY Change 71.35% -45.87%
FREE CASH FLOW
Cash From Operating Activities -$2.387M -$1.312M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q3 us-gaap Treasury Stock Value
TreasuryStockValue
1 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
578578 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
738789 usd
CY2024Q3 INBS Research And Development Tax Incentive Receivable Current
ResearchAndDevelopmentTaxIncentiveReceivableCurrent
648334 usd
CY2024Q3 us-gaap Liabilities
Liabilities
5776641 usd
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
43775 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
61207017 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54649965 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-496259 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
6104567 usd
CY2024Q3 us-gaap Minority Interest
MinorityInterest
-155325 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
5949242 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11725883 usd
CY2024Q3 dei Trading Symbol
TradingSymbol
INBS
CY2024Q3 dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
CY2024Q3 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q3 dei Entity File Number
EntityFileNumber
001-39825
CY2024Q3 dei Entity Registrant Name
EntityRegistrantName
Intelligent Bio Solutions Inc.
CY2024Q3 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q3 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-1512711
CY2024Q3 dei Entity Address Address Line1
EntityAddressAddressLine1
Intelligent Bio Solutions Inc
CY2024Q3 dei Entity Address Address Line2
EntityAddressAddressLine2
135 West, 41ST Street
CY2024Q3 dei Entity Address Address Line3
EntityAddressAddressLine3
5th Floor
CY2024Q3 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2024Q3 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2024Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10036
CY2024Q3 dei City Area Code
CityAreaCode
(646)
CY2024Q3 dei Local Phone Number
LocalPhoneNumber
828-8258
CY2024Q3 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q2 INBS Deferred Charges
DeferredCharges
usd
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
usd
CY2024Q3 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
usd
CY2024Q3 us-gaap Inventory Write Down
InventoryWriteDown
usd
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
usd
CY2024Q3 INBS Fair Value Gain On Revaluation Of Holdback Series Preferred Stock
FairValueGainOnRevaluationOfHoldbackSeriesPreferredStock
usd
CY2024Q3 INBS Increase Decrease In Grant Receivable And Deferred Grant Income
IncreaseDecreaseInGrantReceivableAndDeferredGrantIncome
usd
CY2023Q3 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
usd
CY2023Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
CY2023Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
CY2023Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2023Q3 INBS Equity Issuance Costs In Accounts Payable And Accrued Expenses
EquityIssuanceCostsInAccountsPayableAndAccruedExpenses
usd
CY2024Q3 dei Document Type
DocumentType
10-Q
CY2024Q3 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q3 dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
CY2024Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q3 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q3 dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4386816 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3989431 usd
CY2024Q3 INBS Deferred Charges
DeferredCharges
127586 usd
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
396193 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
6478911 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
586120 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
260760 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
4400092 usd
CY2024Q3 us-gaap Assets
Assets
11725883 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1834416 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
281565 usd
CY2024Q3 us-gaap Deferred Income Current
DeferredIncomeCurrent
2585696 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
477517 usd
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
499605 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5678799 usd
CY2024Q3 INBS Employee Related Liabilities Noncurrent
EmployeeRelatedLiabilitiesNoncurrent
69731 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28111 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4377759 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4377759 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3456000 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3456000 shares
CY2024Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
116 shares
CY2024Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
116 shares
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
872287 usd
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
525486 usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
563763 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
346801 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
232331 usd
CY2024Q3 us-gaap Government Assistance Operating Income
GovernmentAssistanceOperatingIncome
126128 usd
CY2023Q3 us-gaap Government Assistance Operating Income
GovernmentAssistanceOperatingIncome
109871 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1949016 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2457060 usd
CY2024Q3 INBS Development And Regulatory Approval Expenses
DevelopmentAndRegulatoryApprovalExpenses
948752 usd
CY2023Q3 INBS Development And Regulatory Approval Expenses
DevelopmentAndRegulatoryApprovalExpenses
103947 usd
CY2024Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300422 usd
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
307560 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
3198190 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2868567 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2725261 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2526365 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
22327 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
37448 usd
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-51 usd
CY2023Q3 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
131250 usd
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
52840 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
139 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
30462 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
93941 usd
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-2694799 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-2432424 usd
CY2024Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-9166 usd
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-7220 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2685633 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2425204 usd
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
216355 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-18016 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
216355 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-18016 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-2478444 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-2450440 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-9166 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-7220 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2469278 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2443220 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.70
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.70
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-12.48
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-12.48
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3811090 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3811090 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
194200 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
194200 shares
CY2024Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-12
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8183191 usd
CY2024Q3 INBS Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
7939 usd
CY2024Q3 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
190045 usd
CY2024Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
12000 usd
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
34511 usd
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
216355 usd
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-2694799 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
5949242 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3686998 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3686998 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-18016 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-2432424 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1236558 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1236558 usd
CY2024Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-12
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-2694799 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-2432424 usd
CY2024Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
241622 usd
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
247598 usd
CY2024Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
61489 usd
CY2023Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
59962 usd
CY2023Q3 us-gaap Inventory Write Down
InventoryWriteDown
67851 usd
CY2024Q3 us-gaap Share Based Compensation
ShareBasedCompensation
202045 usd
CY2024Q3 INBS Non Cash Refund Of Research And Development Expenditure Claims
NonCashRefundOfResearchAndDevelopmentExpenditureClaims
86037 usd
CY2023Q3 INBS Non Cash Refund Of Research And Development Expenditure Claims
NonCashRefundOfResearchAndDevelopmentExpenditureClaims
33523 usd
CY2023Q3 INBS Fair Value Gain On Revaluation Of Holdback Series Preferred Stock
FairValueGainOnRevaluationOfHoldbackSeriesPreferredStock
-131250 usd
CY2024Q3 INBS Noncash Other Operating Activities
NoncashOtherOperatingActivities
33170 usd
CY2023Q3 INBS Noncash Other Operating Activities
NoncashOtherOperatingActivities
-104485 usd
CY2024Q3 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
148874 usd
CY2023Q3 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
273649 usd
CY2024Q3 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-38748 usd
CY2023Q3 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
53035 usd
CY2023Q3 INBS Increase Decrease In Grant Receivable And Deferred Grant Income
IncreaseDecreaseInGrantReceivableAndDeferredGrantIncome
97128 usd
CY2024Q3 INBS Increase Decrease In Research And Development Tax Incentive Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxIncentiveReceivable
123002 usd
CY2023Q3 INBS Increase Decrease In Research And Development Tax Incentive Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxIncentiveReceivable
60830 usd
CY2024Q3 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
127586 usd
CY2024Q3 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-101379 usd
CY2023Q3 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-139486 usd
CY2024Q3 us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
221335 usd
CY2023Q3 us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
1215964 usd
CY2024Q3 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
6116 usd
CY2023Q3 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
2830 usd
CY2024Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-46482 usd
CY2023Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-68170 usd
CY2024Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2387216 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1311833 usd
CY2024Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
34511 usd
CY2024Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
7939 usd
CY2024Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
42450 usd
CY2024Q3 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
30099 usd
CY2023Q3 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-39010 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2314667 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1350843 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6304098 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1537244 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3989431 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
186401 usd
CY2024Q3 INBS Equity Issuance Costs In Accounts Payable And Accrued Expenses
EquityIssuanceCostsInAccountsPayableAndAccruedExpenses
127586 usd
CY2024Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
3000000.0 usd
CY2024Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
34511 usd
CY2024Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
17167 shares
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2685633 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2425204 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
5949242 usd
CY2024Q3 INBS Working Capital Deficit
WorkingCapitalDeficit
800112 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54649965 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3990000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
216355 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
18016 usd
CY2024Q3 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_840_eus-gaap--UseOfEstimates_z4heeXKYRzT4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zKRxsjAcunhi">Use of estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Significant estimates made by management in connection with the preparation of the accompanying consolidated financial statements including the fair value measurement of and the useful lives of long-lived assets, inventory valuations, the allocation of transaction price among various performance obligations, and the allowance for credit losses. Actual results could materially differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2024Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2024Q3 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_z8a8Wh4PmW8a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zewkmF9qwMUa">Concentration of credit risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company places its cash and cash equivalents, which may at times be in excess of the Australia Financial Claims Scheme, Financial Services Compensation Scheme or the United States’ Federal Deposit Insurance Corporation insurance limits, with high credit quality financial institutions and attempts to limit the amount of credit exposure with any one institution. No losses have been incurred to date on any deposits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
CY2024Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 usd
CY2023Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
872287 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
796094 usd
CY2021Q2 us-gaap Deferred Income
DeferredIncome
4700000 usd
CY2024Q3 us-gaap Construction In Progress Gross
ConstructionInProgressGross
568678 usd
CY2024Q2 us-gaap Construction In Progress Gross
ConstructionInProgressGross
543410 usd
CY2024Q3 INBS Research And Development Tax Refund
ResearchAndDevelopmentTaxRefund
110087 usd
CY2023Q3 INBS Research And Development Tax Refund
ResearchAndDevelopmentTaxRefund
76348 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
872287 usd
CY2024Q3 us-gaap Government Assistance Operating Income
GovernmentAssistanceOperatingIncome
126128 usd
CY2024Q3 us-gaap Revenues
Revenues
998415 usd
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-2694799 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
796094 usd
CY2023Q3 us-gaap Government Assistance Operating Income
GovernmentAssistanceOperatingIncome
109871 usd
CY2023Q3 us-gaap Revenues
Revenues
905965 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-2432424 usd
CY2024Q3 us-gaap Noncurrent Assets
NoncurrentAssets
5246972 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
738789 usd
CY2024Q3 INBS Long Lived Assets And Inventory
LongLivedAssetsAndInventory
5985761 usd
CY2024Q2 us-gaap Noncurrent Assets
NoncurrentAssets
5244620 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
777537 usd
CY2024Q2 INBS Long Lived Assets And Inventory
LongLivedAssetsAndInventory
6022157 usd
CY2024Q3 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
219050 usd
CY2024Q2 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
188693 usd
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
519739 usd
CY2024Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
588844 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
738789 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
777537 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
5463000 usd
CY2024Q3 INBS Effect Of Foreign Currency On Intangible Assets
EffectOfForeignCurrencyOnIntangibleAssets
998882 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2061790 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
4400092 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
5463000 usd
CY2024Q2 INBS Effect Of Foreign Currency On Intangible Assets
EffectOfForeignCurrencyOnIntangibleAssets
632878 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1723852 usd
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
4372026 usd
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
235464 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
243153 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
703306 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
863222 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
838382 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
838382 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
838382 usd
CY2024Q3 INBS Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
209596 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4291270 usd
CY2024Q3 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 usd
CY2024Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.0097 pure
CY2024Q3 INBS Percentage Of Gross Revenue Received
PercentageOfGrossRevenueReceived
0.10 pure
CY2024Q3 INBS Percentage Of Sales To Distributor
PercentageOfSalesToDistributor
0.50 pure
CY2024Q3 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
61489 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
59962 usd
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
12734 usd
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
21171 usd
CY2024Q3 us-gaap Lease Cost
LeaseCost
74223 usd
CY2023Q3 us-gaap Lease Cost
LeaseCost
81133 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y1M6D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.132 pure
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y3M18D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.132 pure
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
246773 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
87990 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
334763 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
25087 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
309676 usd
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5516754 shares
CY2024Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
3000000.0 usd
CY2024Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
34511 usd
CY2024Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
17167 shares
CY2024Q3 us-gaap Stock Issued During Period Shares Employee Stock Ownership Plan
StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
99500 shares
CY2024Q3 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
190045 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.91
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2685633 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2425204 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.70
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.70
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-12.48
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-12.48
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3811090 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3811090 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
194200 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
194200 shares
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001493152-24-043927-index-headers.html Edgar Link pending
0001493152-24-043927-index.html Edgar Link pending
0001493152-24-043927.txt Edgar Link pending
0001493152-24-043927-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
inbs-20240930.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
inbs-20240930_cal.xml Edgar Link unprocessable
inbs-20240930_def.xml Edgar Link unprocessable
inbs-20240930_lab.xml Edgar Link unprocessable
inbs-20240930_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending